Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Atrial Fibrillation Raises Dementia Risk

XTALKS VITALS NEWS

Atrial Fibrillation

The researchers compared patients with atrial fibrillation with those who did not suffer from the condition, and found that the former patients were between two and three times more likely to develop dementia in their lives.

Share this!

November 24, 2016 | by Sarah Hand, M.Sc.

Patients with an abnormal heart rhythm – known as atrial fibrillation – are at risk of experiencing a stroke due to the formation of small blood clots in the heart. In order to treat this condition, patients are prescribed blood thinner drugs, such as warfarin, which prevent the blood from clotting.

Now, researchers at the Intermountain Medical Center Heart Institute, have shown that atrial fibrillation patients taking warfarin are at an increased risk of developing dementia, compared to those taking the blood thinner for other medical conditions. As warfarin is the most commonly-prescribed anticoagulant drug, this research suggests that the drug itself is not the only factor contributing to the commonality of dementia among certain patient groups.

In their study, the researchers analyzed the medical records of over 6,000 patients who were chronically using warfarin for any indication. None of the patients had a history of dementia.

The researchers compared patients with atrial fibrillation with those who did not suffer from the condition, and found that the former patients were between two and three times more likely to develop dementia in their lives. In order to make this comparison, the study investigators controlled for multiple confounding factors which could increase the risk of dementia.



“Atrial fibrillation patients are at higher risk of developing all forms of dementia compared to patients without atrial fibrillation,” said Dr. Jared Bunch, lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City. “Warfarin is used to lower risk of stroke in patients with atrial fibrillation, but when the blood levels of the drug are erratic, it contributes to the dementia risk. This dementia risk is observed in people with and without atrial fibrillation that are exposed to long-term warfarin treatment.”

Previous research at Intermountain has shown that patients with atrial fibrillation have increased rates of dementia, including Alzheimer’s disease. Bunch and his team plan to conduct further studies to determine which treatments may be tied to dementia in these patients.

“Even when we consider the influence of warfarin on dementia risk, the presence of atrial fibrillation conveys additional risk of dementia,” said Bunch. “This suggests that the way we manage the abnormal heart rhythm, beyond just the practice of preventing blood clots through warfarin, may be a way we can further lower the risk of all forms of dementia, including Alzheimer’s disease, in patients with atrial fibrillation.”


Keywords: Atrial Fibrillation, Dementia, Blood Thinners


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.